Agios Pharmaceuticals, Inc. AGIO
32.58
(0.32)
(0.97%)
as of 25 Sep
- Market cap
- $2.0B
- P/E
- 0.0×
Follow AGIO
Growth Flags
show if company had growth for consecutive years
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
52.10 | 29.21 | 30.11 | 22.45 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(26.47) | (16.40) | (16.72) | (38.52) | |
P/B ratio |
1.82 | 1.32 | 1.79 | 2.15 | |
Price to Tangible BV |
1.82 | 1.32 | 1.79 | 2.15 | |
EV/Sales |
32.19 | 14.52 | 19.87 | 16.79 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(3.52) | (2.10) | (3.45) | (4.58) | |
EV/FCF |
(3.48) | (2.08) | (3.41) | (4.52) | |
Quick Ratio |
12.81 | 10.52 | 12.80 | 9.08 | |
Current Ratio |
13.82 | 11.46 | 14.19 | 10.22 | |
Net Debt/EBITDA |
8.13 | 7.00 | 6.71 | 5.60 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.03 | 0.04 | 0.05 | 0.08 | |
Operating CF/Net income |
0.85 | 0.89 | 1.20 | 0.57 | |
Capex/Depreciation |
5.18 | 2.30 | (3.51) | (5.43) | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
673.88% | 441.01% | 391.15% | 225.17% | |
Selling, General and Administrative Expense of Revenue |
320.45% | 258.48% | 232.84% | 115.20% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
96.09% | 70.74% | 74.91% | 35.63% | |
Graham Net Nets |
0.40 | 0.53 | 0.38 | 0.29 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(17.39%) | (26.12%) | (21.43%) | (18.89%) | |
Free Cash Flow Yield |
(17.74%) | (23.91%) | (19.35%) | (16.54%) | |
Revenue per Share |
0.22 | 0.34 | 0.35 | 0.75 | |
Operating CF per Share |
(1.52) | (1.66) | (2.02) | (0.96) | |
Capex per Share |
(0.03) | (0.02) | (0.01) | (0.02) | |
Free Cash Flow per Share |
(1.54) | (1.68) | (2.04) | (0.98) | |
Cash per Share |
16.39 | 14.74 | 12.54 | 10.38 | |
Shareholders Equity per Share |
22.09 | 20.58 | 18.87 | 17.25 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
22.09 | 20.58 | 18.87 | 17.25 | |
Free Cash Flow |
(89.71) | (97.33) | (119.69) | (58.52) | |
Working Capital |
958.35 | 859.85 | 776.00 | 647.45 | |
Capital Expenditures |
(1.55) | (1.12) | (0.77) | (1.21) | |
Net Current Asset Value |
931.73 | 837.94 | 758.97 | 635.27 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.12 | 0.06 | 0.04 | 0.03 | |
Net Profit Margin |
(803.05%) | (541.09%) | (477.74%) | (225.06%) | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
4.07 | 7.34 | 9.74 | 12.55 | |
Average Payables |
18.35 | 17.50 | 13.74 | 16.94 | |
Average Inventory |
29.23 | 30.27 | 32.35 | 30.50 | |
Average Assets |
1,588.75 | 1,480.21 | 1,370.25 | 1,289.83 | |
Average Common Equity |
1,455.50 | 1,367.04 | 1,287.82 | 1,197.79 |
Columns are period end dates